CAPR
Capricor Therapeutics, Inc. NASDAQ Listed Feb 13, 2007$33.94
Mkt Cap $1.6B
52w Low $4.30
82.2% of range
52w High $40.37
50d MA $31.42
200d MA $18.22
P/E (TTM)
-13.7x
EV/EBITDA
-9.9x
P/B
4.7x
Debt/Equity
0.1x
ROE
-34.4%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
0.48
50d MA
$31.42
200d MA
$18.22
Avg Volume
1.3M
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
10865 Road to the Cure · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.51 | -0.62 | -21.6% | 33.42 | -1.3% | -8.7% | -8.6% | -6.7% | -7.5% | -6.7% | — |
| Nov 10, 2025 | AMC | -0.54 | -0.54 | +0.0% | 5.56 | +5.9% | +11.5% | +5.6% | +3.8% | +0.7% | +2.3% | — |
| Aug 11, 2025 | AMC | -0.48 | -0.57 | -18.8% | 7.82 | +0.4% | +2.8% | +6.1% | -0.5% | +1.8% | -1.5% | — |
| May 13, 2025 | AMC | -0.33 | -0.53 | -60.6% | 7.30 | +6.0% | +5.1% | +31.0% | +29.3% | +42.1% | +50.8% | — |
| Mar 19, 2025 | AMC | -0.31 | -0.16 | +48.4% | 12.22 | +2.8% | +17.5% | +5.2% | +8.7% | +10.3% | +7.9% | — |
| Nov 13, 2024 | AMC | -0.36 | -0.38 | -5.6% | 16.91 | +0.1% | +9.3% | +10.1% | +8.7% | +9.2% | +11.9% | — |
| Aug 7, 2024 | AMC | -0.36 | -0.35 | +2.8% | 3.56 | +12.9% | +9.0% | +5.6% | +10.1% | +10.4% | +7.3% | — |
| May 13, 2024 | AMC | -0.11 | -0.31 | -181.8% | 5.44 | -5.7% | -4.4% | -2.0% | +3.7% | +14.0% | +15.8% | — |
| Feb 29, 2024 | AMC | -0.09 | -0.02 | +77.8% | 4.20 | +5.5% | +8.8% | +11.2% | +18.1% | +23.6% | +20.0% | — |
| Nov 14, 2023 | AMC | -0.29 | -0.25 | +13.8% | 3.01 | -0.3% | +6.6% | +2.3% | +1.0% | -1.3% | -3.0% | — |
| Aug 7, 2023 | AMC | -0.35 | -0.29 | +17.1% | 4.71 | +0.0% | +21.7% | +25.3% | +26.5% | +28.2% | +40.3% | — |
| May 11, 2023 | AMC | -0.32 | -0.31 | +3.1% | 4.11 | -0.7% | -1.9% | +1.9% | +3.2% | +5.8% | +12.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $33.42 | $33.00 | -1.3% | -8.7% | -8.6% | -6.7% | -7.5% | -6.7% |
| Mar 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.42 | $33.00 | -1.3% | -8.7% | -8.6% | -6.7% | -7.5% | -6.7% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.42 | $33.00 | -1.3% | -8.7% | -8.6% | -6.7% | -7.5% | -6.7% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.63 | $32.50 | +6.1% | +9.0% | +9.6% | +9.1% | -0.4% | -0.2% |
| Dec 15 | B. Riley Securities | Maintains | Buy → Buy | — | $26.02 | $25.87 | -0.6% | +2.0% | +0.0% | +0.5% | +0.7% | +6.9% |
| Dec 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $27.38 | $28.30 | +3.4% | +4.7% | -0.7% | -5.0% | -3.0% | -5.0% |
| Dec 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $26.89 | $26.60 | -1.1% | +6.2% | +1.8% | +6.6% | +1.1% | -3.2% |
| Dec 4 | Maxim Group | Maintains | Buy → Buy | — | $29.96 | $28.25 | -5.7% | -15.2% | -10.2% | -4.7% | -8.6% | -4.3% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.36 | $30.00 | +371.7% | +371.1% | +299.4% | +322.8% | +349.1% | +330.5% |
| Nov 12 | Roth Capital | Maintains | Buy → Buy | — | $6.20 | $6.18 | -0.3% | -5.3% | -6.9% | -9.7% | -8.2% | -9.0% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.19 | $6.81 | +10.0% | +5.3% | +14.5% | +19.7% | +16.5% | +26.3% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.33 | $6.11 | -3.5% | +1.7% | +0.5% | -4.6% | -1.7% | -3.9% |
| Jul 14 | Roth Capital | Maintains | Buy → Buy | — | $7.64 | $7.39 | -3.3% | -3.3% | -6.0% | -5.2% | -6.3% | -9.9% |
| Jul 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.40 | $7.00 | -38.6% | -33.0% | -35.2% | -37.0% | -36.5% | -37.2% |
| Jun 25 | Jones Trading | Maintains | Buy → Buy | — | $9.25 | $9.24 | -0.1% | +8.6% | +10.1% | +20.5% | +7.4% | +4.9% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.68 | $7.90 | +2.9% | +20.4% | +30.9% | +32.6% | +45.2% | +29.3% |
| Jun 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $8.26 | $8.00 | -3.1% | -7.0% | +12.0% | +21.7% | +23.2% | +35.0% |
| Jun 17 | Roth Capital | Maintains | Buy → Buy | — | $12.38 | $12.12 | -2.1% | -1.5% | -3.6% | -33.3% | -38.0% | -25.3% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.94 | $13.55 | -2.8% | -15.5% | -11.2% | -12.6% | -14.3% | -40.7% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.30 | $7.74 | +6.0% | +5.1% | +31.0% | +29.3% | +42.1% | +50.8% |
| Mar 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $12.22 | $12.56 | +2.8% | +17.5% | +5.2% | +8.7% | +10.3% | +7.9% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.22 | $12.56 | +2.8% | +17.5% | +5.2% | +8.7% | +10.3% | +7.9% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.23 | $13.32 | +0.7% | -2.6% | -12.2% | -7.6% | +8.5% | -2.8% |
| Mar 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.67 | $15.11 | +10.5% | +0.2% | -7.5% | -0.6% | -6.3% | -9.7% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.80 | $14.02 | +1.6% | +8.4% | +13.1% | +8.7% | +3.0% | +0.4% |
| Nov 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.91 | $16.92 | +0.1% | +9.3% | +10.1% | +8.7% | +9.2% | +11.9% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.91 | $16.92 | +0.1% | +9.3% | +10.1% | +8.7% | +9.2% | +11.9% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.84 | $4.81 | -0.6% | -2.5% | -0.2% | -0.6% | -1.4% | -5.2% |
| May 14 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $5.44 | $5.13 | -5.7% | -4.4% | -2.0% | +3.7% | +14.0% | +15.8% |
| May 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.44 | $5.13 | -5.7% | -4.4% | -2.0% | +3.7% | +14.0% | +15.8% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.44 | $5.13 | -5.7% | -4.4% | -2.0% | +3.7% | +14.0% | +15.8% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.04 | $5.06 | +0.4% | +2.2% | +7.3% | +5.8% | +4.6% | +5.8% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.20 | $4.43 | +5.5% | +8.8% | +11.2% | +18.1% | +23.6% | +20.0% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $3.10 | +6.9% | -2.1% | -2.1% | +0.0% | -4.1% | -1.7% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.61 | $6.69 | +1.2% | +8.0% | +0.5% | +11.0% | +4.5% | +16.6% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.47 | $4.47 | +0.0% | +2.0% | -2.9% | +0.2% | -1.6% | -4.3% |
| Oct 26 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $5.73 | $5.98 | +4.4% | +6.3% | +0.9% | -2.4% | -3.0% | -5.1% |
| Jan 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.15 | $3.17 | +0.6% | +13.3% | +16.5% | +18.7% | +31.1% | +34.6% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.73 | $3.94 | +5.6% | +9.1% | +6.7% | +10.5% | +11.5% | +6.2% |
| Nov 25 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.03 | $4.00 | -0.7% | +0.0% | +6.5% | +4.2% | +3.2% | +2.7% |
| Nov 25 | Roth Capital | Maintains | Buy → Buy | — | $4.03 | $4.00 | -0.7% | +0.0% | +6.5% | +4.2% | +3.2% | +2.7% |
| Nov 25 | Maxim Group | Maintains | Buy → Buy | — | $4.03 | $4.00 | -0.7% | +0.0% | +6.5% | +4.2% | +3.2% | +2.7% |
| Jul 15 | H.C. Wainwright | Maintains | Buy → Buy | — | $3.22 | $7.15 | +122.0% | +93.5% | +86.3% | +77.0% | +63.0% | +75.2% |
| Jul 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.22 | $7.15 | +122.0% | +93.5% | +86.3% | +77.0% | +63.0% | +75.2% |
| Dec 31 | H.C. Wainwright | Maintains | Buy → Buy | — | $3.70 | $3.70 | +0.0% | +10.8% | +35.1% | +29.7% | +37.8% | +67.6% |
| Dec 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.70 | $3.70 | +0.0% | +10.8% | +35.1% | +29.7% | +37.8% | +67.6% |
| May 16 | Maxim Group | Maintains | Buy → Buy | — | $13.00 | $13.40 | +3.1% | +2.3% | +4.6% | +6.2% | +6.2% | +6.2% |
| Jun 15 | Roth Capital | Maintains | Buy → Buy | — | $35.40 | $35.40 | +0.0% | +17.2% | +34.2% | +26.0% | +25.1% | +22.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Bergmann Anthony | CHIEF FINANCIAL OFFICER | Sell | 25,000 | $31.70 | $793K | 8,223 | -1.61% | — |
| May 1, 2026 | Krasney Karen | EVP, GENERAL COUNSEL | Sell | 25,000 | $31.70 | $793K | 30,547 | -1.61% | — |
8-K
Unknown — 8-K Filing
Capricor's deramiocel BLA submission for Duchenne muscular dystrophy represents a significant clinical milestone that could drive near-term revenue growth if approved, making this a pivotal moment for shareholders.
Mar 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
This boilerplate disclaimer suggests CAPR disclosed material information but provided minimal specifics, leaving investors unable to assess fundamental impacts on valuation or business operations.
Mar 10
Data updated apr 24, 2026 11:49pm
· Source: massive.com